Toxoplasmosis in a Patient Receiving Ixekizumab for Psoriasis

JAAD Case Reports - United States
doi 10.1016/j.jdcr.2020.01.005
Full Text
Abstract

Available in full text

Categories
Dermatology
Date
Authors
Publisher

Elsevier BV

Related search

Real-World Drug Survival of Ixekizumab for Psoriasis

Journal of the American Academy of Dermatology
Dermatology
2019English

Emerging Targeted Therapies for Plaque Psoriasis &Ndash; Impact of Ixekizumab

Clinical, Cosmetic and Investigational Dermatology
Dermatology
2017English

Ixekizumab: Targeting Plaque Psoriasis and Psoriatic Arthritis

Prescriber
Pharmacology
2019English

Fatal, Incidental, Idiopathic Pulmonary Fibrosis in a Patient Receiving Long‐term Low‐dose Methotrexate for Psoriasis

Clinical and Experimental Dermatology
Dermatology
2019English

713 the Association Between Disease Severity at Time of Retreatment and Probability of Recapture in Psoriasis Patients Receiving Ixekizumab

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Ixekizumab Efficacy and Safety in Moderate-To-Severe Genital Psoriasis

British Journal of Dermatology
DermatologyMedicine
2018English

Cerebral Toxoplasmosis in an AIDS Patient.

Internal Medicine
Internal MedicineMedicine
2003English

Spotlight on Ixekizumab for the Treatment of Moderate-To-Severe Plaque Psoriasis: Design, Development, and Use in Therapy

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2017English

567 Stability of PASI 90 Response in Psoriasis Patients Treated With Ixekizumab or Ustekinumab

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy